Japan Tobacco (2914) Q4 2024 earnings summary

Executive summary

• Achieved record-high consolidated revenue and adjusted operating profit (AOP) in 2024, driven by strong tobacco and processed food businesses, while pharmaceutical performance declined.

• The acquisition of Vector Group in the U.S. significantly contributed to Q4 2024 results and expanded presence in the U.S. market, with full-year benefits expected in 2025.

• Business Plan 2025 targets high single-digit AOP growth at constant FX from 2025–2027, supported by tobacco, RRP expansion, and pricing strategies.

• Shareholder returns prioritized with a dividend payout ratio target of about 75% and annual dividend per share of JPY 194 for 2024 and 2025.

Financial highlights

• FY2024 core revenue at constant FX: JPY 2,958.4bn (+8.4% YoY); reported revenue: JPY 3,149.8bn (+10.9% YoY); AOP at constant FX: JPY 782.7bn (+7.5% YoY).

• Operating profit rose 3.7% YoY to JPY 697.2bn; profit attributable to owners fell 3.9% to JPY 463.4bn due to higher financial costs.

• Free cash flow decreased to JPY 170.5bn, mainly due to Vector acquisition payments.

• 2025 forecast: Core revenue at constant FX to rise 6.6%, AOP at constant FX to grow 8.4% YoY, with full-year Vector contribution.

• Annual dividend per share maintained at JPY 194, payout ratio 74.3%.

Outlook and guidance

• FY2025 core revenue at constant FX forecasted at JPY 3,232.0bn (+6.6% YoY); AOP at constant FX at JPY 815.0bn (+8.4% YoY).

• Operating profit projected to decline 3.8% to JPY 671.0bn due to higher amortization and FX headwinds.

• Business Plan 2025 targets high single-digit average annual AOP growth at constant FX from 2025–2027.

• Tobacco business AOP at constant FX projected to grow 8.1% YoY in 2025, with volume expected to decline 1–2% due to industry contraction.

• Pharmaceutical AOP to decrease due to higher R&D, while processed food AOP to grow modestly.